Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 3/2020

01-07-2020 | Lymphoma | Original Article

Clinical Effect of CD25 on the Prognosis of Diffuse Large B Cell Lymphoma with Secondary Central Nervous System Relapse

Authors: Satoko Oka, Kazuo Ono, Masaharu Nohgawa

Published in: Pathology & Oncology Research | Issue 3/2020

Login to get access

Abstract

In the present study, we investigated the effects of immunophenotyping on prognosis of diffuse large B cell lymphoma (DLBCL) with central nervous system (CNS) relapse treated with rituximab-CHOP (R-CHOP). CNS relapse occurred in 9.5% of DLBCL patients. At the diagnosis of DLBCL, CD25 was detected in 14.3% of cases. CD25 positivity correlated with an advanced stage, higher R-IPI, higher CNS-IPI, the presence of B symptoms, the presence of extranodal involvement >1, and bone involvement. Moreover CNS relapse was more frequently observed in patients with CD25+ than in those with CD25-. The univariate analysis showed that an advanced stage, high-risk R-IPI, high-risk CNS-IPI, bone involvement, and CD25+ were associated with shorter overall survival (OS). The multivariate analysis confirmed that CD25+ and high-risk CNS-IPI were independent adverse prognostic factors for shorter OS. A Kaplan-Meier analysis revealed the potential of CD25+ as a prognostic factor in patients with CNS relapse and that it correlated with shorter survival. The present results showed that the expression of CD25 in DLBCL patients with CNS relapse was associated with the patient prognosis independent other prognostic factors. The establishment of a treatment strategy for CNS relapse patients with CD25+ DLBCL cells is needed to improve poor outcomes.
Literature
1.
Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, Schmitz N, German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) (2007) Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German high-grade non-Hodgkin's lymphoma study group (DSHNHL). Ann Oncol 18:149–157CrossRef
2.
Tomita N, Yokoyama M, Yamamoto W, Watanabe R, Shimazu Y, Masaki Y, Tsunoda S, Hashimoto C, Murayama K, Yano T, Okamoto R, Kikuchi A, Tamura K, Sato K, Sunami K, Shibayama H, Takimoto R, Ohshima R, Hatta Y, Moriuchi Y, Kinoshita T, Yamamoto M, Numata A, Ishigatsubo Y, Takeuchi K (2012) Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era. Cancer Sci 103:245–251CrossRef
3.
Avilés A, Jesús Nambo M, Neri N (2013) Central nervous system prophylaxis in patients with aggressive diffuse large B cell lymphoma: an analysis of 3,258 patients in a single center. Med Oncol 30:520CrossRef
4.
Chihara D, Oki Y, Matsuo K, Onoda H, Taji H, Yamamoto K, Morishima Y (2011) Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: analyses with competing risk regression model. Leuk Lymphoma 52:2270–2275CrossRef
5.
Tai WM, Chung J, Tang PL, Koo YX, Hou X, Tay KW, Quek R, Tao M, Lim ST (2011) Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab. Ann Hematol 90:809–818CrossRef
6.
Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, Glass B, Scott DW, Gascoyne RD, Connors JM, Ziepert M, Pfreundschuh M, Loeffler M, Savage KJ (2016) CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 34:3150–3156CrossRef
7.
Chin CK, Cheah CY (2017) How I treat patients with aggressive lymphoma at high risk of CNS relapse. Blood. 130:867–874CrossRef
8.
Hu W, Wang X, Yang R, Bi L, Xie Y, Zhang Z, Lu H, Wu L (2017) Expression of CD56 is a risk factor for acute lymphocytic leukemia with central nervous system involvement in adults. Hematology. 22:81–87CrossRef
9.
Alinari L, Gru A, Quinion C, Huang Y, Lozanski A, Lozanski G, Poston J, Venkataraman G, Oak E, Kreisel F, Park SI, Matthews S, Abramson JS, Iris Lim H, Martin P, Cohen JB, Evens A, al-Mansour Z, Singavi A, Fenske TS, Blum KA (2016) De novo CD5+ diffuse large B-cell lymphoma: adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort. Am J Hematol 91:395–399CrossRef
10.
Flynn MJ, Hartley JA (2017) The emerging role of anti-CD25 directed therapies as both immune modulators and targeted agents in cancer. Br J Haematol 179:20–35CrossRef
11.
Nakase K, Kita K, Anazawa H, Hoshino K, Shirakawa S, Tanaka I, Tsudo M (1994) Induction of interleukin-2 receptor alpha chain expression of immature acute myelocytic leukemia cells. Leuk Res 18:269–274CrossRef
12.
Nakase K, Kita K, Nasu K, Ueda T, Tanaka I, Shirakawa S, Tsudo M (1994) Differential expression of interleukin-2 receptors (alpha and beta chain) in mature lymphoid neoplasms. Am J Hematol 46:179–183CrossRef
13.
Tesch H, Günther A, Abts H et al (1993) Expression of interleukin-2R alpha and interleukin-2R beta in Hodgkin's disease. Am J Pathol 142:1714–1720PubMedPubMedCentral
14.
Waldmann TA (2007) Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J Clin Immunol 27:1–18CrossRef
15.
Hashimoto Y, Yokohama A, Saitoh A, Nakahashi H, Toyama K, Mitsui T, Koiso H, Saitoh T, Handa H, Uchiumi H, Jinbo T, Murayama K, Matsumoto M, Sawamura M, Karasawa M, Murakami H, Hirato J, Nojima Y, Kojima M, Tsukamoto N (2013) Prognostic importance of the soluble form of IL-2 receptorα (sIL-2Rα) and its relationship with surface expression of IL-2Rα (CD25) of lymphoma cells in diffuse large B-cell lymphoma treated with CHOP-like regimen with or without rituximab: a retrospective analysis of 338 cases. J Clin Exp Hematop 53(3):197–205CrossRef
16.
Yoshida N, Oda M, Kuroda Y et al (2013) Clinical significance of sIL-2R levels in B-cell lymphomas. PLoS One 8:e78730CrossRef
17.
Geng H, Brennan S, Milne TA et al (2012) Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. Cancer Discov 2:1004–1023CrossRef
18.
Lee JW, Chen Z, Geng H et al (2015) CD25(IL2RA) orchestrates negative feedback control and stabilizes oncogenic signaling strength in acute lymphoblastic leukemia. Blood 126:1434CrossRef
19.
Fujiwara S, Muroi K, Hirata Y, Sato K, Matsuyama T, Ohmine K, Suzuki T, Ozaki K, Mori M, Nagai T, Tanaka A, Ozawa K (2013) Clinical features of de novo CD25(+) diffuse large B-cell lymphoma. Hematology. 18:14–19CrossRef
20.
Fujiwara S, Muroi K, Tatara R, Matsuyama T, Ohmine K, Suzuki T, Mori M, Nagai T, Tanaka A, Ozawa K (2014) Clinical features of de novo CD25-positive follicular lymphoma. Leuk Lymphoma 55:307–313CrossRef
21.
Ibrahim S, Keating M, Do KA et al (2001) CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood. 98:181–186CrossRef
22.
Tanimoto T, Kusumi E, Hosoda K et al (2012) CNS prophylaxis in diffuse large B-cell lymphoma. Lancet. 379:1485–1486CrossRef
23.
Oki Y, Noorani M, Lin P et al (2014) Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol 166:891–901CrossRef
24.
Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, Shah KA, Whyman JD, Lansigan F, Hernandez-Ilizaliturri FJ, Lee LX, Barta SK, Melinamani S, Karmali R, Adeimy C, Smith S, Dalal N, Nabhan C, Peace D, Vose J, Evens AM, Shah N, Fenske TS, Zelenetz AD, Landsburg DJ, Howlett C, Mato A, Jaglal M, Chavez JC, Tsai JP, Reddy N, Li S, Handler C, Flowers CR, Cohen JB, Blum KA, Song K, Sun HL, Press O, Cassaday R, Jaso J, Medeiros LJ, Sohani AR, Abramson JS (2014) Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 124:2354–2361CrossRef
25.
Feugier P, Virion JM, Tilly H, Haioun C, Marit G, Macro M, Bordessoule D, Recher C, Blanc M, Molina T, Lederlin P, Coiffier B (2004) Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol 15:129–133CrossRef
26.
Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ (2010) Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol 21:1046–1052CrossRef
27.
Yamamoto W, Tomita N, Watanabe R, Hattori Y, Nakajima Y, Hyo R, Hashimoto C, Motomura S, Ishigatsubo Y (2010) Central nervous system involvement in diffuse large B-cell lymphoma. Eur J Haematol 85:6–10PubMed
28.
Shahab N, Doll DC (1999) Testicular lymphoma. Semin Oncol 26:259–269PubMed
29.
Zucca E, Conconi A, Mughal TI, Sarris AH, Seymour JF, Vitolo U, Klasa R, Ozsahin M, Mead GM, Gianni MA, Cortelazzo S, Ferreri AJ, Ambrosetti A, Martelli M, Thiéblemont C, Moreno HG, Pinotti G, Martinelli G, Mozzana R, Grisanti S, Provencio M, Balzarotti M, Laveder F, Oltean G, Callea V, Roy P, Cavalli F, Gospodarowicz MK, International Extranodal Lymphoma Study Group (2003) Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the international Extranodal lymphoma study group. J Clin Oncol 21:20–27CrossRef
30.
Chua SL, Seymour JF, Streater J, Wolf MM, Januszewicz EH, Prince HM (2002) Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma 43:1783–1788CrossRef
31.
Kumar A, Vanderplas A, LaCasce AS, Rodriguez MA, Crosby AL, Lepisto E, Czuczman MS, Nademanee A, Niland J, Gordon LI, Millenson M, Zelenetz AD, Friedberg JW, Abel GA (2012) Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer. 118:2944–2951CrossRef
32.
Phillips EH, Kirkwood AA, Lawrie A et al (2016) Low rates of CNS relapse in high risk DLBCL patients treated with R-CODOX-M and R-IVAC: results from a phase 2UK NCRI/Bloodwise trial. Blood 128:1855CrossRef
33.
Grommes C, Tang SS, Wolfe J, Kaley TJ, Daras M, Pentsova EI, Piotrowski AF, Stone J, Lin A, Nolan CP, Manne M, Codega P, Campos C, Viale A, Thomas AA, Berger MF, Hatzoglou V, Reiner AS, Panageas KS, DeAngelis L, Mellinghoff IK (2019) Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. Blood. 133:436–445CrossRef
34.
Rubenstein JL, Geng H, Fraser EJ, Formaker P, Chen L, Sharma J, Killea P, Choi K, Ventura J, Kurhanewicz J, Lowell C, Hwang J, Treseler P, Sneed PK, Li J, Wang X, Chen N, Gangoiti J, Munster PN, Damato B (2018) Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2:1595–1607CrossRef
Metadata
Title
Clinical Effect of CD25 on the Prognosis of Diffuse Large B Cell Lymphoma with Secondary Central Nervous System Relapse
Authors
Satoko Oka
Kazuo Ono
Masaharu Nohgawa
Publication date
01-07-2020
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 3/2020
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-019-00778-y

Other articles of this Issue 3/2020

Pathology & Oncology Research 3/2020 Go to the issue

Original Article

Prognostic and Clinicopathological Correlations of Cell Cycle Marker Expressions before and after the Primary Systemic Therapy of Breast Cancer

Original Article

Positive Correlative over-Expression between eIF4E and Snail in Nasopharyngeal Carcinoma Promotes its Metastasis and Resistance to Cisplatin

Original Article

Identification of Key Genes and Signaling Pathways Associated with the Progression of Gastric Cancer

Original Article

Development and Validation of a Model for Predicting Intravesical Recurrence in Organ-confined Upper Urinary Tract Urothelial Carcinoma Patients after Radical Nephroureterectomy: a Retrospective Study in One Center with Long-term Follow-up

Original Article

Leiomyoma with Bizarre Nuclei: a Study of 108 Cases Focusing on Clinicopathological Features, Morphology, and Fumarate Hydratase Alterations

Original Article

Identification of GIMAP7 and Rabl3 as Putative Biomarkers for Oral Squamous Cell Carcinoma Through Comparative Proteomic Approach

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits